H.C. Wainwright reiterates Mineralys stock rating on new data
H.C. Wainwright reiterated a Buy rating and $56.00 price target for Mineralys Therapeutics (NASDAQ:MLYS), citing new clinical data for lorundrostat. The target implies 140% upside from the current stock price of $23.37. The firm highlights the drug's potential in treating difficult-to-treat hypertension ahead of a December 2026 PDUFA date. Mineralys reported a wider-than-expected Q2 2026 loss of $2.85 per share. UBS initiated coverage with a Neutral rating and $29.00 price target.
How this was made
The 30-second read
Why it matters
The analyst upgrade could drive short-term buying interest, but ultimate price movement depends on FDA approval timing.
Market read
The news is relevant for traders focused on biotech equities and FDA‑driven catalysts.
What to watch
Potential competition from other aldosterone synthase inhibitors not discussed.
Background
Mineralys Therapeutics presented new clinical data on lorundrostat at a major cardiology conference and received an analyst rating upgrade.
Ticker impact
H.C. Wainwright reiterated a Buy rating and raised the price target to $56 on new hypertension trial data, a fresh analyst action after the company's Q2 loss was already disclosed.
likely upward pressure as investors price in the higher target and positive trial data
The new target represents a 140% upside from the current price, indicating strong buy sentiment.
Market effects
Positive data may boost sentiment for hypertension therapeutics and related biotech stocks.
Limited to U.S. biotech sector.
Modest; primarily affects investors tracking US-listed biotech.
Counterpoint
If the FDA delays approval, the target may be overly optimistic.
Key entities
- CompanyMineralys Therapeutics, Inc.
Biotech firm developing hypertension drug lorundrostat.
- AnalystH.C. Wainwright
Equity research firm that issued the Buy rating and $56 target.
